BioSpace News Archive

A delay in returning its Lotus Edge Aortic Valve System to the market has cost Boston Scientific an estimated $3B loss in market capitalization.

Ardelyx will receive a $30 million upfront payment and is eligible to receive additional development and commercialization milestones worth up to $130 million.

This next-generation solution, which has been certified by Veeva to meet its technology partner program standards--provides “right time” integration of AHM’s CentrisDirect with Veeva CRM Events Management to minimize compliance risk.

The Zen Edition prioritizes intelligent workflow and patient comfort, providing clinical applications to help providers make accurate diagnoses.

BD has amended the Exchange Offers and Consent Solicitations to extend the expiration date of the Exchange Offers and Consent Solicitations from 12:01 a.m., New York City time, on November 28, 2017 to 5:00 p.m., New York City time, on December 14, 2017 which date and time may be modified as described below.

The application is based on results from the Phase 3 CheckMate -214 study.

ABX-1431 was generally safe and well-tolerated.

If this sNDA is approved, the labeled indication for Trelegy Ellipta would include a wider population of patients with COPD who are at risk of an exacerbation and require triple therapy.

Nuvo’s common shares will continue to trade on the Toronto Stock Exchange under the symbol “NRI”.

Top-line data showed that the trial achieved its primary endpoint, demonstrating statistically significant, dose dependent increases in lean body mass, less head, following treatment with VK5211 as compared to placebo.